ALPINE IMMUNE SCIENCES INC (ALPN)
US02083G1004 - Common Stock
ALPINE IMMUNE SCIENCES INC
NASDAQ:ALPN (4/18/2024, 7:00:00 PM)
After market: 64.43 0 (0%)64.43
-0.03 (-0.05%)
Company Profile
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 126 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Company Info
ALPINE IMMUNE SCIENCES INC
188 East Blaine St., Suite 200
Seattle WASHINGTON 98102
P: 12067884545
CEO: Mitchell H. Gold
Employees: 126
ALPN News
a day ago - The Motley FoolDoes This Acquisition Make Vertex Pharmaceuticals Stock a Buy?The biotech just added another potential growth driver to its pipeline.
The biotech just added another potential growth driver to its pipeline.
4 days ago - InvestorPlaceCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year.
4 days ago - The Motley FoolHere's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals StockVertex just laid claim to an asset that might be very valuable.
Vertex just laid claim to an asset that might be very valuable.
6 days ago - The Motley FoolCould This Stock Be the Next Biotech Buyout?Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
ALPN Twits
Here you can normally see the latest stock twits on ALPN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
